CONQUERORSThe Campaign to Conquer Cancer

CONQUERORS

Campaign Report and 2017 Financials

THE

$167MThe Celebration 1The Priorities 2

The Hypothesis 3 The Impact 4

Women Who Conquer Cancer (WWCC) 5The Survivor & The Scientist 6-7

The Champions 8-9The Matchmaker 10-11The Investigator 12-13

The Innovator 14-15The Stakeholders 16-17

The Sustainers 18-192017 Financials 20

The Work Continues 21

TABLE OF CONTENTS

It is uncommon to use the words “cancer” and “celebration” in the same context, but as confetti fell on June 3, 2017, the moment was worth marking: The Campaign to Conquer Cancer – the first comprehensive fundraising effort of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) – had surpassed its $150 million fundraising goal six months early!

Your donation to The Campaign is also worth commemorating. As told by the survivors who benefit from your generosity, the doctors whose research you fuel, and fellow donors who share your urgency to conquer cancer now, The Conquerors showcases what we are doing, together, to make a cancer diagnosis less scary for everyone.

In the years since The Campaign began, we can report life-changing therapies uncovered by the brilliant scientists you support, advances in quality patient care through your investments in CancerLinQ®, global health improvements through international grant expansion, and continued opportunities for patients, doctors, and caregivers to access the latest cancer care information.

We share these stories with immense gratitude. Please read and discover the impact your donation is making with assurance that you, too, are among The Conquerors. Thank you for helping raise nearly $167 million to improve cancer care for every patient, everywhere.

$167M

Thomas G. Roberts, Jr.MD, FASCO Chair

1

THE CELEBRATION

Clifford A. HudisMD, FACP, FASCO Chief Executive Officer

Nancy R. DalyMS, MPH Executive Vice-President and Chief Philanthropic Officer

THE PRIORITIES

Breakthrough Research

Quality of Care

Education

Global Oncology

Priority Goal (in Millions) Total Raised (in Millions)

Research $56 $54.2

Quality of Care $40 $30.3

Education $35 $36

Global Oncology $4 $3.3

Unrestricted/Other* $15 $43.1

Total $150 $166.9

*Approximately 49% of unrestricted/other donations are re-directed to support programs in Research, Education, and Quality of Care.

As the first major fundraising effort of our growing foundation, The Campaign was — to speak in research terms — a case study. Could a relatively unknown charity earn the support of new donors to forward its ambitious mission? We believed the answer to be yes, and no one supported our hypothesis more than the members of the Campaign Cabinet. Make no mistake: This group was not a random sample. Each dedicated volunteer united with purpose to guide our protocol. We are grateful for their leadership and expertise in proving our theory:Together, we can conquer cancer.

“I agreed to be honorary co-chair for The Campaign to Conquer Cancer to

continue to broaden the base, because more people need to know about what

this foundation accomplishes, and more people need to give so that more great

work can be done. This is how we will take down cancer. And in my mind, it starts

and ends with cancer doctors.”

— Desirée Rogers

THE HYPOTHESIS

Honorary Campaign Co-Chair Desirée Rogers speaks during The Campaign Kickoff Dinner on Saturday, May 30, 2015, during the ASCO Annual Meeting. The dinner celebrated the launch of The Campaign.

3

CAMPAIGN CABINET MEMBERS

Desirée Rogers Honorary Co-Chair

Claire A. Huang Co-Chair

Robert J. Mayer, MD, FASCO Co-Chair

Thomas G. Roberts, Jr., MD, FASCOCo-Chair (2015)

Fred Gaudelli

Francine Pepitone

Steven T. Rosen, MD, FACP, FASCO

*Approximately 49% of unrestricted/other donations are re-directed to support programs in Research, Education, and Quality of Care.

Grants and Awards

Distributed

People who attended an

educational event

Educational Awards

Distributed

438 269,279 1,258

“The fact that we exceeded our fundraising goal is a testament to the

importance of this work and we are grateful that many supporters recognize

this. The Campaign continues to be important because we have not conquered

the disease. We believe that our continuing efforts to raise funds will be the

start of the end of cancer.”

— Claire A. Huang, co-chair of The Campaign to Conquer Cancer

THE IMPACT

2012 - 2017

“The steady guidance of a supportive mentor who was committed to helping me

flourish as a professional made a profound and lasting impression on me. I am

honored to be the first recipient of an award that calls attention to such an

important part of our profession – mentorship.”

— Sarah S. Donaldson, MD, FASCO

Dr. Donaldson, a globally-recognized pediatric radiation oncology expert, receives the inaugural Women Who Conquer Cancer Mentorship Award in 2016 from Julie M. Vose, MD, MBA, FASCO. This award honoring influential women mentors underscores the critical role mentors play in cancer care.

Dr. Sarah S. Donaldson is a professor at Stanford University School of Medicine and chief of radiation oncology at the Packard Children’s Hospital in Stanford, California. Her decades-long research and contributions related to improving quality of treatment and of life for children with cancer is matched only by the guidance she has long offered her peers.

WWCC Mentorship

Awards Given

3WWCC Young Investigator

Awards Distributed

10

5

Women Who Conquer Cancer (WWCC) stands in the gap to provide funding and mentorship to early-career female oncologists.

During The Campaign, WWCC funded its first Young Investigator Award (YIA) and began raising awareness and funds to support women in

cancer research and care.

“My participation is allowing others to receive a treatment with a stage IV

diagnosis, not a death sentence.”

— Brittany Sullivan

Brittany Sullivan is a six-time cancer survivor and a Conquer Cancer volunteer.

She lives in Tennessee with her husband, John, and their daughter, Carly Jean.

Dr. Breelyn Wilky is a sarcoma medical oncologist at Sylvester Comprehensive Cancer Center in Miami, where she lives with her husband. She is an assistant professor at the University of Miami Miller School of Medicine.

THE SURVIVOR

Early phase clinical trials, where new therapies are first tested in patients, are the heart of cancer research to me. This is where laboratory discoveries make the leap from bench to bedside and where hope abounds for the new breakthroughs, especially for uncommon cancers.

Rare diseases lack research dollars and a lack of patients to enroll on large clinical trials. In 2012, I applied for and received a Conquer Cancer Young Investigator Award. This award funded me for a fourth year of fellowship, so I could finish and publish my research on a new drug for sarcoma patients. For me and so many other awardees, a YIA is a launching pad for these early, critical moments in our research careers. For me, this has meant the opportunity to compete and receive additional grants, explore more trials and treatments, and meet patients like Brittany. Patients like her, who provide the inspiration, are the catalyst to success stories.

In our happily ever-afters, we so easily forget that cancer can happen to anyone, that none of us are immune. In 2012, a very thorough team of doctors discovered a sizable tumor inside my heart while I was pregnant. By 2014, the cancer had spread to my brain. I chose to participate in a research trial because it was my only option. I’d spent a lifetime hoping that my Alveolar Soft Part Sarcoma (ASPS) wouldn’t metastasize, because every medical resource declared stage IV ASPS a death sentence. When my oncologist said there may be hope with Dr. Wilky’s clinical trial, I jumped all over it. In that moment, cancer research gave me hope that there would be life without cancer again. Indeed, there will be.

It wasn’t until later in my story that I was able to recognize the significance of the research element of my treatment. My participation is allowing others to receive a treatment with a stage IV diagnosis, not a death sentence. A twenty-something mom and her little miracle girl convey that reality in a powerful way. This is a miraculous feat accomplished through your generous support and Dr. Wilky’s creative initiative.

7

THE SCIENTISTSarcomas may be rare compared to breast or colon cancer, but rare diseases don’t

seem very rare to the patients or the doctors conquering them every day.

“The fundamental goal of Genentech-funded pioneering projects is to spark

innovation so that it can play a key role in supporting the work that matters

most. Genentech believes that this is only possible if others support this effort.”

— Dietmar Berger, MD, Senior Vice President of Genentech Global Clinical Development

THE CHAMPIONS

Genentech BioOncology™, a member of the Roche Group, is a world leader in biotechnology and is the largest donor to The Campaign to Conquer Cancer, a founding donor to Conquer Cancer’s Mission Endowment, a CancerLinQ® stakeholder, a major supporter of ASCO Meetings, and a dedicated Grants & Awards funder.

$1 millionIn 2017, Jaime Libes, MD, MPH, receives a Career Development Award supported by Genentech to research pediatric oncology.

9

CAMPAIGN CHAMPIONS DONATED

$1 millionor more.

Anonymous

Raj Mantena, RPh

Thomas G. Roberts, Jr., MD, and Susan M. DaSilva, PhD

Aaron and Barbro Sasson

CORPORATIONS

NON-PROFITS

INDIVIDUALS

Raj Mantena attends Conquer Cancer Day at Wrigley Field in Chicago, June 1, 2016.

Integra Connect, where Mantena is Chairman and Founder, sponsored a golf tournament in 2017 to benefit Conquer Cancer. Raj Mantena is joined by professional golfers Ernie Els, Jack Nicklaus, and Luke Donald along with his brother Raju Mantena at the event, which raised more than $1 million.

© ASCO/Todd Buchanan 2016

THE MATCHMAKER

In 2011, The Campaign launched in a silent phase with a major gift. Raj Mantena became the first individual donor to give $1 million. But he didn’t stop there. To motivate others to give, he offered three challenges throughout The Campaign where he matched donors’ gifts.

An entrepreneur, Mantena has founded or co-founded several groundbreaking oncology companies. At the forefront of each is a genuine concern for increasing the quality of care received by patients while simultaneously improving the efficiency of patient treatment. In Conquer Cancer, Mantena saw “authenticity and credibility.” He was especially motivated to invest in CancerLinQ® because “it is going to provide researchers and clinicians with critical, comprehensive information about the treatment of cancer patients and will result in more amazing health outcomes in the future.”

Helping patients with cancer is at the core of Conquer Cancer’s mission.

The Campaign provided the opportunity to introduce more people to the work our donors support and inspired thousands to join our community

of conquerors.

53% of donors

increased their support

of Conquer Cancer

during the Campaign

The number of donors

grew by 897%

since 2012

Friends of Conquer Cancer

hosted intimate events

where people who

learned about our mission

contributed nearly

$2 million

53% 897% $1.95M

11

Dr. Katherine Van Loon, a 2012 Young Investigator Award recipient, speaks at an event hosted by Dr. Sarah Donaldson to raise funds for Women Who Conquer Cancer.

Young Investigator Awards allow early-career scientists the opportunity to explore innovative research during the

transition from a fellowship program to a faculty appointment. This is often the first major funding a recipient has earned, but it is rarely the last. Considered a career-catalyst, many YIA recipients go on to receive additional funding. During their careers, these researchers have launched clinical studies, discovered new treatments, and revealed unique information that is improving cancer care for patients everywhere.

Breast Cancer Research Foundation® funded Conquer Cancer’s first endowed

YIA in 2012, in memory of Evelyn H. Lauder. Since 2001, BCRF has invested

more than $10 million in support of 69 breast cancer research grants through

Conquer Cancer.

“Today’s young investigators are tomorrow’s innovators, and our partnership

with Conquer Cancer allows us to foster this intellectual pool.”

— Myra Biblowit, President & CEO, Breast Cancer Research Foundation

Young Investigator Awards

The Young Investigator Award truly gave me a lot of courage and ability to experiment with novel approaches in developing a pre-clinical model for triple-negative breast cancer. From a career perspective, the YIA helped me to become much more competitive and assisted me in acquiring an academic clinician-scientist position.

Saima Hassan, MD, PhD, 2013 Young Investigator Award Recipient

With the support provided by the Conquer Cancer YIA, our group has been able to continue research that is directly leading to increased treatment options for women with aggressive forms of breast cancer. Not only has this award aided scientific discovery and clinical progress, it has enabled discovery that has the potential to impact thousands of women with cancer.

Corey Speers, MD, PhD, 2014 Young Investigator Award Recipient

A Conquer Cancer first:

In 2017, donors provided

enough funding to award

YIAs to all meritorious

applicants.

It started as a single grant for one doctor. It continues as a new way to help patients conquer one of the deadliest forms of cancer.

In 2013, Supriya Saha, MD, PhD, was a fellow at Massachusetts General Hospital when he received a Young Investigator Award supported by The Cholangiocarcinoma Foundation. With it, he would target certain mutations in cholangiocarcinoma, a highly lethal malignancy of the liver bile ducts.

Dr. Saha’s research at Mass Gen would be recognized for publication in major scientific journals and by the National Institutes of Health. Additional grant dollars followed.

In 2016, Saha would again partner with The Cholangiocarcinoma Foundation, this time to open a state-of-the-art lab bearing his name.

The Saha Laboratory for Liver Cancer Translational Research, part of the Fred Hutch Cancer Research Center in Seattle, is revolutionizing prevention, detection and treatment for cholangiocarcinoma, and a former Conquer Cancer grantee is leading the way.

Dr. Saha receives a Young Investigator Award in 2013 from then-Conquer Cancer Chair W. Charles Penley, MD, FASCO.

13

THE INVESTIGATOR

cholangiocarcinomathe

foundation

International Innovation Grants (IIG) debuted in 2014, expanding Conquer Cancer’s global reach. Chibuike Chigbu, MBBS, FWACS, of the University of Nigeria, served as principal investigator for one of the first projects supported by an IIG.

&QuestionAnswer

What led you to apply for the IIG?I provided free cervical and breast cancer prevention education and services to several thousands of women in southeast Nigeria through a self-funded nongovernmental organization, the Women Life Care Foundation. The charity work exposed me to two hypotheses, that 1) a community engagement approach, and 2) home-delivered cancer prevention education might provide the missing link in the quest for improved population awareness of cervical and breast cancer prevention. The scientific testing of this hypothesis was the objective of the IIG, which I received in 2014.

What were the results?The results of the study showed that the intervention of home-delivered cervical and breast cancer prevention education significantly increased awareness and voluntary uptake of cervical and breast cancer prevention services.

The outcome of the study was published in the June 2017 edition of the International Journal of Gynecology and Obstetrics.1

How is your research advancing progress against cancer, both in Nigeria and globally?The results of the study will help guide policy development on cervical and breast cancer prevention in Nigeria and similar low-income settings. The study has proven that an integrated cervical and breast cancer prevention program based on health education of the population and prevention services provision at the primary health care level is feasible and effective. Enhanced cancer prevention services utilization will contribute significantly towards reducing the burden of cancer in low-resource settings like Nigeria.

Why is the IIG a valuable research funding mechanism?The strength lies in the novelty and innovative nature of the grant projects. The grant encourages innovative, effective, and culturally sensitive solutions to cancer. I find this very important, as many internationally proven solutions to cancer prevention encounter severe challenges of implementation when deployed to resource-constrained regions. By encouraging local innovative ideas, ASCO and Conquer Cancer are taking a front seat in the drive towards the reduction of the cancer burden in Africa and other low-income regions of the world.

Chibuike Chigbu, MBBS, FWACS

© ASCO/Danny M

orton 2016

THE INNOVATOR

1. Chigbu CO, Onyebuchi AK, Onyeka TC, et al. Int J Gynaecol Obstet. 2017;137:319-24.

IDEA recipients during the Grants & Awards Ceremony and Reception, June 4, 2017.

© ASCO/Danny M

orton 2016

International Development

and Education Award (IDEA)

IDEA recipients are paired

with a leading ASCO member

mentor, attend the

ASCO Annual Meeting,

participate in a post-Meeting

visit to their mentor’s

institution, and develop

long-term relationships to

improve cancer care in their

countries. In addition,

IDEA recipients receive

three years of complimentary

ASCO membership, including

a subscription to the Journal of Clinical Oncology.

Long-term International

Fellowship (LIFe)

LIFe funds a one-year

mentorship for

early-career physicians

in low-income

countries to learn

from established

doctors in

the United States,

Canada, or European

Union.

International Innovation

Grant (IIG)

The IIG provides research

funding in support of

novel and innovative

projects that can have

a significant impact on

cancer control in low- and

middle-income countries.

It is intended to support

proposals that

have the potential to

reduce the cancer burden

in local communities, while

also being potentially

transferable to nations with

similar economies.

120 13 12Number of International Grants and Awards Distributed (2012-2017)

15

“By understanding how patients are actually treated, the side effects

experienced, and the clinical utility of treatment in the non-research setting,

there is no question that oncologists will be in a far better position to

effectively manage the care provided to their patients.”

— Maurie Markman, MD, President of Medicine and Science, Cancer Treatment Centers of America (CTCA)

“Consistent with our commitment to the care and treatment of our patients,

the development of CancerLinQ will bring the newest evidence-based therapies

directly to the patient,” said Raj Garg, MD, JD, President and CEO of CTCA.

“We believe that CancerLinQ ranks among the most exciting developments

in the evolution of cancer care. We have been delighted to contribute to its

development and implementation for the benefit of

cancer patients everywhere.”

© ASCO/Todd Buchanan 2016

THE STAKEHOLDERS

CancerLinQ launched, in part, thanks to support from Conquer Cancer, whose generous donors have helped make the system possible.

Major Supporters

Amgen | Astellas | AstraZeneca | Bayer HealthCare Pharmaceuticals Inc. | Boehringer Ingelheim Pharmaceuticals, Inc. | Cancer Treatment Centers of America® | Chan Soon-Shiong Family Foundation | Genentech BioOncology™ | HELSINN | Janssen Oncology | Lilly | Raj Mantena, RPh | Novartis Oncology | Pfizer Oncology | Thomas G. Roberts, Jr., MD, and Susan M. DaSilva, PhD | Susan G. Komen®

CancerLinQ® is a health information technology platform aimed at improving the quality of cancer care using

real-world cancer data. Nearly $27 million in Campaign support from Conquer Cancer donors helped CancerLinQ:

Sign 100 US oncology practices

Form key partnerships with private technology companies and health associations to accelerate the pace of information sharing

© ASCO/Todd Buchanan 2016

17

Clinical trials collect data on only 3% of adult patients with cancer. Conquer Cancer-supported CancerLinQ will help doctors learn from the other 97%.

cancerlinq.org

Practices in 40 states and Washington, DC, representing more than 2,000 oncologists, have contributed more than 1 million cancer patient records.

THE SUSTAINERS

Until her death in 2015, Anna Braglia supported the mission and growth of HELSINN, her family’s pharmaceutical group dedicated to building quality cancer care. Her passion endures in the Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by HELSINN.

“She cared passionately both about encouraging high quality research in oncology

and about fostering entrepreneurship . . . We believe young people are key to the

future of medical innovation and of our industry.”

— Riccardo Braglia, Helsinn Group Vice Chairman and CEO, says of his mother.

Merit Awards make it possible for a fellow or oncology trainee to present a research abstract at the ASCO Annual Meeting or other symposia. During The Campaign, 1,012 Merit Awards were given, fostering the idea of information sharing on which ASCO was founded. Dr. Frances A. Shepherd became the first donor to endow a Merit Award in 2017.

&QuestionAnswer

Why is donor-supported research critical to conquering cancer?These days, research dollars are getting tighter and tighter. ASCO and Conquer Cancer’s help in that domain is extremely important. What I particularly value about many of Conquer Cancer’s awards is that they focus on young oncologists in their first few years of practice. This is the time when it is so critical, and yet so difficult, to get grant funding.

What area of focus will your award support?This merit award has some strings attached. First, it is for a woman trainee. Second, it is specifically for lung cancer research. If research funding, in general, has been, and remains, difficult to get, research funding for lung cancer over the last few decades has been considerably less well supported at all granting levels.

Dr. Shepherd is a professor of medicine at the University of Toronto.

Endowed Fund Supporters

American Society of Clinical Oncology

Anonymous

Friends and Family of Dr. and Mrs. Ronald Beller

Dr. and Mrs. Douglas W. Blayney

Boehringer Ingelheim International GmbH

Breast Cancer Research Foundation®

Bristol-Myers Squibb

Celgene Corporation

Estate of Darla C. Ellis

GlaxoSmithKline Oncology

HELSINN

Hologic, Inc

Loxo Oncology

Friends and Family of Dr. James B. Nachman

Dr. Kathleen Pritchard Medicine Professional Corporation

Thomas G. Roberts, Jr., MD, and Susan M. DaSilva, PhD

Aaron and Barbro Sasson

Frances A. Shepherd, MD, FASCO

Stephen A. Sherwin, MD

Drs. Rachna and Puneet Shroff

Walther Cancer Foundation

Generous Supporters of the Women Who Conquer Cancer

19

“It is our hope that this gift provides consistent, dependable support for the

top young investigators of oncology today and encourages the rising leaders

of tomorrow to pursue a career in research.”

— Barbro Sasson, with husband Aaron, funded the Åke Bertil Eriksson Endowed Young Investigator Award in memory of her father, who died from cancer in 1988.

Inaugural recipient David Kurtz, MD, (inset and above with donors Barbro and Aaron Sasson) studied lymphoma with the 2016 Åke Bertil Eriksson Endowed YIA.

12 Young Investigator Awards

endowed during The Campaign ensure

consistent research funding

12

Thomas G. Roberts, Jr., MD, FASCO, Chair

Sandra M. Swain, MD, FACP, FASCO, Treasurer

Claire A. Huang, Secretary

Clifford A. Hudis, MD, FACP, FASCO, CEO

Daniel F. Hayes, MD, FASCO,ASCO President(June 6, 2016 – June 5, 2017)

Bruce E. Johnson, MD, FASCO,ASCO President(June 5, 2017 – June 4, 2018)

Nancy R. Daly, MS, MPHExecutive Vice President & Chief Philanthropic Officer

Howard A. Burris, III, MD, FACP, FASCO

Alexander W. Casdin

Susan L. Cohn, MD, FASCO

Lawrence H. Einhorn, MD, FASCO

Raj Mantena, RPh

Thomas A. Marsland, MD, FASCO

Robert J. Mayer, MD, FASCO

Gerald J. McDougall

W. Charles Penley, MD, FASCO, Chair Emeritus

Steven T. Rosen, MD, FACP, FASCO

Aaron A. Sasson

Margaret A. Tempero, MD, FASCO

Don Welsh

2017 Board of Directors

2017 FINANCIALS

REVENUES Corporate 15,610,268Foundation 9,231,050Individual 4,365,558TOTAL REVENUES 29,206,876

EXPENSES Programs 20,667,382Fundraising 3,735,885Administration 332,336TOTAL EXPENSES 24,735,603

Operating Income 4,471,273

Long Term Investment 5,180,817

Change in Net Assets 9,652,090 Change in Unrestricted Net Assets 6,193,319 Change in Restricted Net Assets 3,458,771

Unrestricted Net Assets Beginning of Year 30,337,459Restricted Net Assets Beginning of Year 25,182,002

Unrestricted Net Assets End of Year 36,530,778Restricted Net Assets End of Year 28,640,773• Corporate 53.4%

• Foundation 31.6%

• Individual 14.9%

• Programs 84%

• Fundraising 15%

• Administration 1%

21

THE WORK CONTINUES

In 1964, when chemotherapy was just emerging as a treatment, seven oncologists created ASCO. They believed that combining efforts to better understand cancer through research and information-sharing could help turn science into a sigh of relief for patients and their loved ones.

As ASCO’s foundation, Conquer Cancer lights the way for researchers to explore new ideas, connects physicians to learn about the latest advances, and expands access to quality care for every patient, everywhere.

The Campaign was built around the priorities on which ASCO and Conquer Cancer were founded. Though it came to a successful end, our shared mission to conquer cancer remains. And so will the impact of your gifts.

Together with donors like you, Conquer Cancer will continue fueling the brightest minds in cancer research to provide everyone affected by this disease access to the latest information and care.

Thank you for your support.

Mission Endowment Donors

The Mission Endowment extends the reach and impact of the Conquer Cancer mission by providing support to enhance quality and expand access to care for patients in areas of research, professional education, patient education, and international programs.

Founding DonorsGenentech BioOncology™GlaxoSmithKline OncologyNovartis OncologySanofi Genzyme *New Donor or Recent Gift Received (2017-2018)

Sustaining DonorsAbbVie, Inc.*AmgenAstellas*AstraZeneca*Bayer HealthCare Pharmaceuticals Inc.*Celgene CorporationEisai Inc.EMD Serono Inc.*

Gilead Sciences, Inc.HELSINNIncyte CorporationIntegra ConnectLillyLoxo Oncology*PharmaMar*Sanofi GenzymeTakeda Oncology*

Click here for a list of 2017 donors:

https://www.conquer.org/our-supporters/donors

Conquer Cancer Foundation | 2318 Mill Road, Suite 800 | Alexandria, VA 22314 | 571-483-1700

CONQUER.ORG